Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.
about
Targeting DNA Replication Stress for Cancer TherapyTrial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyDNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of CancerTargeting the Checkpoint to Kill Cancer CellsPerspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancerA synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancersNon-thermal plasma-induced apoptosis is modulated by ATR- and PARP1-mediated DNA damage responses and circadian clockPotentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrencesDevelopment of synthetic lethality anticancer therapeutics.ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisationRequirement of ATR for maintenance of intestinal stem cells in aging DrosophilaDNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity.Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.DNA damage-induced ATM- and Rad-3-related (ATR) kinase activation in non-replicating cells is regulated by the XPB subunit of transcription factor IIH (TFIIH).The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer.ATR Kinase Inhibition Protects Non-cycling Cells from the Lethal Effects of DNA Damage and Transcription Stress.APOBEC3A damages the cellular genome during DNA replicationInhibiting the DNA damage response as a therapeutic manoeuvre in cancer.Cell-free Xenopus egg extracts for studying DNA damage response pathways.Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer.Strategies for optimizing the response of cancer and normal tissues to radiation.Current concepts in clinical radiation oncology.IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting.Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.Neoadjuvant therapy for potentially resectable pancreatic cancer: an emerging paradigm?Targeting chromatin to improve radiation response.Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer.Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways.Molecular Pathways: Targeting ATR in Cancer TherapyPersonalised Medicine: Genome Maintenance Lessons Learned from Studies in Yeast as a Model Organism.DNA replication stress and cancer: cause or cure?TAS-116, a Novel Hsp90 Inhibitor, Selectively Enhances Radiosensitivity of Human Cancer Cells to X-rays and Carbon Ion Radiation.Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.Targeting the ATR-CHK1 Axis in Cancer Therapy
P2860
Q26739923-19484CEE-EDBB-4DC4-B863-A90A9519B503Q26745686-34AA2B1A-D188-448B-90A1-B1AA6CFABBE1Q26776513-F9289495-7731-4933-8BCF-BCE609776CD0Q26795781-ACB76E25-EC15-493F-BBAB-A67E2FE25ED9Q28066320-AEB19059-7D1F-435C-8A8F-CD5262306D01Q28271944-32E93641-94C7-43B1-9379-AF95D476738AQ28821184-1000431D-2498-4002-BC66-3271963D36B0Q34221860-B43C8927-F7E5-43CD-ABCA-B378BDEB28D6Q34354547-315884D0-4C57-4D8E-9EA6-8698BD5488DEQ34380368-B3750253-716A-4614-89FF-AAE1C50BC0B6Q34614944-CFEBBDA9-811A-45F5-B68C-ACA58801AFA4Q35246419-ACBBE738-DA26-4A9D-890C-FA9F4EFEC44BQ35543657-7753F6D3-D8C1-4ABA-9998-B6273D79402FQ35627868-12170632-C814-44F0-AB78-36F40E4CA64FQ35678372-94FFE5B0-B0D7-4DAA-95A6-83F127EF6E4FQ35744967-C65F3372-9C89-43CD-89F2-BE7826F4197DQ36073749-9FC539DC-7E97-429C-81B7-9CA2FAE82234Q36189324-7FD1E7FF-1874-4D16-B8B5-7F386DD6452AQ36395391-C61FD961-6389-446B-88A7-9400F7A888C6Q36688959-E9B771AB-3A42-4A56-B13F-62BAE7C338A0Q36855596-7EFE8943-A7CB-45F9-A41A-6656CEA6BC0DQ36884873-F18EF89F-DE27-41F9-86C1-149FF5B0C782Q36956935-A7C931F0-C01D-486E-8EE8-7342E963AD74Q37122690-3CCD588B-32DB-4834-B1D4-EBE402510571Q37351727-9BA70593-5E8D-4C50-AFDB-5EF02F1E0935Q37499021-5550BA4E-5E67-461A-A503-6A424A2B3CCAQ37531724-26A0F48C-9290-4904-943B-C5C6EBF6CC4BQ37603804-DC2D7FD4-9428-41B8-A582-EFF0CED49146Q37676297-BB6F11DE-3F13-495E-B4F9-742486FF57D5Q37698312-88A82FD7-1646-46BB-BCA7-9765D957B702Q38074622-F4940079-2D25-4C1C-83D7-D42417096474Q38290243-201CEE58-4B89-466B-B14D-D5244DC81A30Q38523589-7E391B15-207D-4426-BD51-0A2241F0C5D3Q38541699-FF67860B-8FAE-43B6-AE52-AED3F3806BBFQ38585436-76E0F82F-E2BB-4B07-8814-E6C7E7C58783Q38608688-31FF8BD0-C422-492F-9D02-4524FAF38FFBQ38652528-7A6B755F-D296-415E-9CA3-30CD87460F8BQ38722571-19CA88A5-D433-448C-B28E-1BDDCD776DD0Q38805276-C1A4DC79-1B07-484B-8184-361535C64903Q38817102-71B01E2E-791A-41D0-AC85-30E41AB8DDF5
P2860
Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Targeting ATR in vivo using th ...... ancreatic tumors to radiation.
@ast
Targeting ATR in vivo using th ...... ancreatic tumors to radiation.
@en
type
label
Targeting ATR in vivo using th ...... ancreatic tumors to radiation.
@ast
Targeting ATR in vivo using th ...... ancreatic tumors to radiation.
@en
prefLabel
Targeting ATR in vivo using th ...... ancreatic tumors to radiation.
@ast
Targeting ATR in vivo using th ...... ancreatic tumors to radiation.
@en
P2093
P2860
P356
P1476
Targeting ATR in vivo using th ...... pancreatic tumors to radiation
@en
P2093
E M Hammond
J R Pollard
M M Olcina
P A Charlton
P M Reaper
R J Muschel
T B Brunner
W Gillies McKenna
P2860
P356
10.1038/CDDIS.2012.181
P577
2012-12-06T00:00:00Z